Treatment of canine atopic dermatitis
AssigneeBenchmark Animal Health Limited
InventorKaspars Tars
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of canine atopic dermatitis (CAD). Furthermore, the invention provides methods for preventing or treating CAD. The compositions of the invention induce efficient immune responses, in particular antibody responses, in dogs and are, therefore, useful for the treatment and/or prevention of CAD.
Claims19
A method of preventing or treating canine atopic dermatitis (CAD) of a canidae, wherein an effective amount of a composition is administered to said canidae, and wherein said composition comprises
- (a) a core particle with at least one first attachment site;
- and
- (b) at least one canine Interleukin-31 antigen (cIL-31 antigen) with at least one second attachment site, wherein said cIL-31 antigen comprises, a protein with the amino sequence selected from SEQ ID NO:22 or a protein with an amino acid sequence of at least 90%, sequence identity with SEQ ID NO:22;
- wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.
A composition comprising
- (a) a virus-like particle (VLP) with at least one first attachment site;
- (b) at least one canine Interleukin-31 antigen (cIL-31 antigen) with at least one second attachment site, wherein said cIL-31 antigen comprises, a protein with the amino acid sequence selected from SEQ ID NO:22 or a protein with an amino acid sequence of at least 90%, sequence identity with SEQ ID NO:22;
- wherein (a) and (b) are linked through said at least one first and said at least one second attachment site via at least one non-peptide covalent bond.
Dependencies are inferred from the claim text.